is the fda banning semaglutide issues warning about some compounded versions of for diabetes, weight loss FDA Drug Recalls and Warnings:

Alvanzo spent twelve years as faculty in the Divisions of General Internal Medicine and Addiction Medicine at Johns Hopkins University School of Medicine where she held a variety of clinical leadership roles, including Associate Medical Director of Addiction Treatment Services and the Center for Addiction and Pregnancy and Medical Director of the Broadway Center for Addiction, comprehensive, outpatient substance use disorder treatment (SUD) programs on the Johns Hopkin Bayview and Johns Hopkins Hospital campuses, respectively

The biggest difference is that injectable forms might cause minor injection-site reactions like redness or itching, which obviously don't occur with the pill

Neither presents a concerning safety picture for most healthy adult researchers, though each has specific considerations worth understanding before starting

Specifically, thyroid function should be rechecked 6-8 weeks after starting or titrating GLP-1 therapy, after significant weight loss, or after any levothyroxine dose change

Eli Lillys orforglipron continues to advance but has not yet reached benchmark weight loss efficacy